Take Your Trading To The Next Level. Get Started Here!

Gilead’s twice-yearly shot cut HIV infections by 96% in trial

September 12, 2024 Comments Off

The data sets the stage for likely approval of Gilead’s Lenacapavir for HIV prevention.